Mechanisms of tumor-induced T cell immune suppression and therapeutics to counter those effects (Q38336989)

2 September 2017

1 reference

title

Mechanisms of tumor-induced T cell immune suppression and therapeutics to counter those effects (English)

1 reference

2 September 2017

Inkyu Hwang

1

1 reference

PubMed ID

25634101

2 September 2017

Nguyet Nguyen

series ordinal

2

1 reference

2 September 2017

30 January 2015

1 reference

Archives of Pharmacal Research

2 September 2017

1 reference

2 September 2017

38

1 reference

2 September 2017

1415-1433

1 reference

2 September 2017

8

1 reference

https://scigraph.springernature.com/pub.10.1007/s12272-015-0566-y

2 September 2017

0 references

cites work

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Targeting the TGFβ signalling pathway in disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

CD39 and CD73 in immunity and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Immunity to methylcholanthrene-induced tumours in inbred rats following atrophy and regression of the implanted tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Dendritic cells and the control of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

CD73: a potent suppressor of antitumor immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

The determinants of tumour immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Targeting damage-associated molecular pattern molecules (DAMPs) and DAMP receptors in melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Central and effector memory CD4 and CD8 T-cell responses to tumor-associated antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Chimeric antigen receptors for T-cell based therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Manipulating immune cells for adoptive immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Current status of interleukin-10 and regulatory T-cells in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Differentiation plasticity regulated by TGF-beta family proteins in development and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Smad-dependent and Smad-independent pathways in TGF-beta family signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Myeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

The three Es of cancer immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Costimulation signals for memory CD8+ T cells during viral infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Activin receptor antagonists for cancer-related anemia and bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

The immune contexture in human tumours: impact on clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Nitration and inactivation of IDO by peroxynitrite

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Mechanisms and functional significance of tumour-induced dendritic-cell defects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

The terminology issue for myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Coordinated regulation of myeloid cells by tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

The immune contexture of primary and metastatic human tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

The cancer vaccine roller coaster

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Antigen degradation or presentation by MHC class I molecules via classical and non-classical pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Dendritic cells in tolerance and autoimmune diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Distinct regulatory CD4+T cell subsets; differences between naïve and antigen specific T regulatory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Regulation of antigen presentation by Mycobacterium tuberculosis: a role for Toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

The C-terminal cysteine-rich region dictates specific catalytic properties in chimeras of the ectonucleotidases NTPDase1 and NTPDase2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Regulation of expression and function of IDO in human dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

TGF-beta signalling from cell membrane to nucleus through SMAD proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Crystal structure of a soluble form of human CD73 with ecto-5'-nucleotidase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Immune suppression in the tumor microenvironment: a role for dendritic cell-mediated tolerization of T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Interleukin 12 signaling in T helper type 1 (Th1) cells involves tyrosine phosphorylation of signal transducer and activator of transcription (Stat)3 and Stat4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Synthetic vaccines: the role of adjuvants in immune targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Blockade of indoleamine 2,3-dioxygenase protects mice against lipopolysaccharide-induced endotoxin shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Toll-like receptors as adjuvant receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

PD-1 and its ligands in tolerance and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Myeloid-derived suppressor cells in cancer: recent progress and prospects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Tumor-associated antigens for specific immunotherapy of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Combination strategies to enhance antitumor ADCC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Overview of cancer vaccines: considerations for development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Unmasking the immune recognition of prostate cancer with CTLA4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Inhibitory MHC class I receptors on NK cells and T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

TGF-beta: a master of all T cell trades

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Transforming growth factor-beta regulation of immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Anti-CD25 mAb administration prevents spontaneous liver transplant tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Going viral with cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Macrophages regulate the angiogenic switch in a mouse model of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Mesenchymal stem cells use IDO to regulate immunity in tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Anti-Gr-1 antibody depletion fails to eliminate hepatic myeloid-derived suppressor cells in tumor-bearing mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Functional alteration of the lymphoma stromal cell niche by the cytokine context: role of indoleamine-2,3 dioxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Immune-based therapies for childhood cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

How tolerogenic dendritic cells induce regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Myeloid-derived suppressor cells in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Antibody-modified T cells: CARs take the front seat for hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Cancer immunotherapy by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

IDO expression by dendritic cells: tolerance and tryptophan catabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Molecular basis for checkpoints in the CD8 T cell response: tolerance versus activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Expression of indoleamine 2,3-dioxygenase and correlation with pathological malignancy in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

TREG-cell therapies for autoimmune rheumatic diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Tolerogenic dendritic cells and the quest for transplant tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Major histocompatibility complex class I-specific receptors on human natural killer and T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

The many face-lifts of CD4 T helper cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Prevention of allogeneic fetal rejection by tryptophan catabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Regulatory T cells in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Adenosine receptors in regulation of dendritic cell differentiation and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Tumor-associated macrophages: from mechanisms to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Regulatory T cells and mechanisms of immune system control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

CD40 and dendritic cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Does the immune system see tumors as foreign or self?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Treating cancer with genetically engineered T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Orchestrating immune check-point blockade for cancer immunotherapy in combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

The roles of TGFβ in the tumour microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Immune suppression by neutrophils and granulocytic myeloid-derived suppressor cells: similarities and differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Microenvironmental regulation of tumor progression and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Metabolism of L-arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Naturally occurring regulatory T cells: recent insights in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Mast cells and macrophages exert beneficial and detrimental effects on tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

CD28 and CTLA-4 coreceptor expression and signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Reversal of the TCR stop signal by CTLA-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Targeting the Transforming Growth Factor-β Signaling in Cancer Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Mechanisms of foxp3+ T regulatory cell-mediated suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Mechanisms of TGF-beta signaling from cell membrane to the nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Cancer/testis antigens, gametogenesis and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

The role of extracellular adenosine in chemical neurotransmission in the hippocampus and Basal Ganglia: pharmacological and clinical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Extracellular adenosine triphosphate and adenosine in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Immunotherapy with gene-modified T cells: limiting side effects provides new challenges.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Ecto-5'-nucleotidase: Structure function relationships

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Immunotherapies for non-small-cell lung cancer and mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Crucial role for ecto-5'-nucleotidase (CD73) in vascular leakage during hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Tumor evasion from T cell surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Cytotoxic human CD4(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

The suppressive tumor microenvironment: a challenge in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Regulation of immunotherapeutic products for cancer and FDA's role in product development and clinical evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Presentation of antigens by MHC class II molecules: getting the most out of them

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Targeting natural killer cells and natural killer T cells in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Homing and cellular traffic in lymph nodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

TGF-beta: a mobile purveyor of immune privilege

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Enhancing adoptive immunotherapy of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Cell-autonomous and -non-autonomous roles of CTLA-4 in immune regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Cytokines of the γ(c) family control CD4+ T cell differentiation and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

HIF-dependent induction of adenosine receptor A2b skews human dendritic cells to a Th2-stimulating phenotype under hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Nucleotide- and nucleoside-converting ectoenzymes: Important modulators of purinergic signalling cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Activin receptor-like kinase5 inhibition suppresses mouse melanoma by ubiquitin degradation of Smad4, thereby derepressing eomesodermin in cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Subsets of myeloid-derived suppressor cells in tumor-bearing mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Crystal structure and mechanism of tryptophan 2,3-dioxygenase, a heme enzyme involved in tryptophan catabolism and in quinolinate biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

A novel role of hematopoietic CCL5 in promoting triple-negative mammary tumor progression by regulating generation of myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Differentiation of effector CD4 T cell populations (*)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Gr-1+CD115+ Immature Myeloid Suppressor Cells Mediate the Development of Tumor-Induced T Regulatory Cells and T-Cell Anergy in Tumor-Bearing Host

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

Divergent effects of hypoxia on dendritic cell functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-015-0566-Y

10.1007/S12272-015-0566-Y

21 January 2018

Identifiers

DOI

1 reference

PubMed ID

25634101

Dimensions Publication ID

2 September 2017

0 references

1 reference

PubMed ID

25634101